Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01365221 · ClinicalTrials.gov registry record · Phase 4

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel

A Phase 4 study of Acute Coronary Syndrome, sponsored by Medstar Health Research Institute.

Completed
Registry status
Phase 4
Development phase
77
Enrollment target
4
Study locations

NCT01365221: Completed Phase 4 study of Acute Coronary Syndrome, sponsored by Medstar Health Research Institute.

NCT01365221 is a Phase 4 study of Acute Coronary Syndrome that has completed, run by Medstar Health Research Institute. The registered enrollment target is 77 participants, below the 2,720-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01365221, a Phase 4 study of Acute Coronary Syndrome, has completed, sponsored by Medstar Health Research Institute.

COMPLETED
Registry status
Phase 4
Development phase
77 participants
Enrollment target
4
Study locations

Study Summary

The primary objective of this study is to compare platelet reactivity between patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.

Conditions Studied

Interventions

  • DRUG Prasugrel

Study Locations (4)

Alabama

  • The Heart Center - Huntsville

District of Columbia

  • Washington Hospital Center - Washington D.C.

Maryland

  • Sinai Center for Thrombosis Research - Baltimore

Missouri

  • Saint Luke's Hospital - Kansas City

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2010-10
Est. Completion 2014-01
Phase Phase 4
Medstar Health Research Institute

115 total trials

What the finished NCT01365221 record still lists

NCT01365221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 2,720-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Prasugrel is the first listed.

NCT01365221 reports a single indexed study location in Alabama, District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT01365221 about?

NCT01365221 is a clinical study titled "The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel". The primary objective of this study is to compare platelet reactivity between patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.

What is the current status of trial NCT01365221?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2010-10. Estimated completion is 2014-01.

What conditions does trial NCT01365221 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT01365221?

The interventions under investigation include: Prasugrel (DRUG).

Who is sponsoring clinical trial NCT01365221?

This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01365221 being conducted?

This trial has 4 study locations across Alabama, District of Columbia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01365221's enrollment target sits among peer trials

77 33rd of 40 higher than 8 of 40 other Acute Coronary Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02127398 · 77 participants · Phase 2

    Stool Transplants to Treat Refractory Clostridium Difficile Colitis

  • NCT04159103 · 77 participants · Phase 1

    Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • NCT04683003 · 77 participants · Phase 3

    A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

  • NCT05004116 · 77 participants · Phase 1

    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01365221, the US trial registry maintained by the National Library of Medicine. NCT01365221 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.